Prometheus Biosciences (NASDAQ:RXDX – Get Rating) was downgraded by equities research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research note issued to investors on Monday, The Fly reports.

Several other research firms have also issued reports on RXDX. The Goldman Sachs Group raised their price objective on Prometheus Biosciences from $117.00 to $144.00 and gave the company a “buy” rating in a research note on Tuesday, January 31st. Guggenheim downgraded Prometheus Biosciences from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $225.00 to $200.00 in a report on Monday. Oppenheimer raised their price objective on Prometheus Biosciences from $125.00 to $150.00 and gave the stock an “outperform” rating in a report on Wednesday, March 1st. Stifel Nicolaus downgraded Prometheus Biosciences from a “buy” rating to a “hold” rating and raised their price objective for the stock from $155.00 to $200.00 in a report on Sunday. Finally, Credit Suisse Group reduced their price objective on Prometheus Biosciences from $142.00 to $139.00 and set an “outperform” rating on the stock in a report on Wednesday, March 1st. Six investment analysts have rated the stock with a hold rating and four have issued  a buy rating to the company. According to data from MarketBeat, Prometheus Biosciences  has a consensus rating of “Hold” and an average price target of $148.70.

NASDAQ:RXDX opened at $193.50 on Monday. The company has a current ratio of 31.04, a quick ratio of 31.04 and a debt-to-equity ratio of 0.04. Prometheus Biosciences has a 12-month low of $21.50 and a 12-month high of $194.99. The stock has a 50-day moving average price of $118.91 and a 200 day moving average price of $93.21. The stock has a market capitalization of $9.20 billion, a P/E ratio of -55.60 and a beta of -0.60.

Prometheus Biosciences (NASDAQ:RXDX – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.01. Prometheus Biosciences had a negative return on equity of 43.38% and a negative net margin of 2,081.83%. The company had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.47 million. Prometheus Biosciences’s revenue was down 37.0% on a year-over-year basis.  Equities research analysts forecast that  Prometheus Biosciences will post -4.03 EPS for the current fiscal year.

In other news, CFO Keith W. Marshall sold 5,000 shares of the firm’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $119.38, for a total value of $596,900.00. Following the completion of the sale, the chief financial officer now owns 9,811 shares of the company’s stock, valued at approximately $1,171,237.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Sinai Intellectual Prop Cedars sold 865,000 shares of the firm’s stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $114.59, for a total value of $99,120,350.00. Following the completion of the sale, the insider now owns 4,001,132 shares of the company’s stock, valued at approximately $458,489,715.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Keith W. Marshall sold 5,000 shares of Prometheus Biosciences stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $119.38, for a total value of $596,900.00. Following the sale, the chief financial officer now directly owns 9,811 shares of the company’s stock, valued at approximately $1,171,237.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 951,320 shares of company stock worth $109,339,563. 3.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RXDX. Swiss National Bank lifted its position in  Prometheus Biosciences by 7.4% during the 1st quarter. Swiss National Bank now owns 27,600 shares of the biopharmaceutical company’s stock worth $1,042,000 after acquiring an additional 1,900 shares during the period.  JPMorgan Chase & Co. boosted its stake in shares of  Prometheus Biosciences by 454.6% in the first quarter. JPMorgan Chase & Co. now owns 82,927 shares of the biopharmaceutical company’s stock worth $3,131,000 after buying an additional 67,975 shares during the last quarter.  Bank of New York Mellon Corp boosted its stake in shares of  Prometheus Biosciences by 10.1% in the first quarter. Bank of New York Mellon Corp now owns 128,626 shares of the biopharmaceutical company’s stock worth $4,857,000 after buying an additional 11,844 shares during the last quarter.  MetLife Investment Management LLC raised its holdings in  Prometheus Biosciences by 55.4% in the 1st quarter. MetLife Investment Management LLC now owns 17,464 shares of the biopharmaceutical company’s stock worth $659,000 after purchasing an additional 6,227 shares during the period.  Finally, Rhumbline Advisers raised its holdings in  Prometheus Biosciences by 3.4% in the 1st quarter. Rhumbline Advisers now owns 37,177 shares of the biopharmaceutical company’s stock worth $1,404,000 after purchasing an additional 1,226 shares during the period. Institutional investors and hedge funds own  78.31% of the company’s stock.

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.

Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.